• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by VYNE Therapeutics Inc. (Amendment)

    2/2/24 9:42:00 AM ET
    $VYNE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VYNE alert in real time by email
    SC 13G/A 1 ea192420-13ga1soleus_vyne.htm AMENDMENT NO. 1 TO SCHEDULE 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

    VYNE Therapeutics Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

     

    92941V 308

    (CUSIP Number)

     

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ☐ Rule 13d-1(b)
      ☒ Rule 13d-1(c)
      ☐ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No.

    92941V 308

     

    1 NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    Soleus Capital Master Fund, L.P.

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

    (a)  ☐

    (b)  ☐

    3 SEC USE ONLY
     
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Cayman Islands

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH

    5 SOLE VOTING POWER

    0

    6 SHARED VOTING POWER
    703,868 (1)
    7 SOLE DISPOSITIVE POWER
    0
    8 SHARED DISPOSITIVE POWER

    703,868 (1) 

    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    703,868 (1)

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

    ☐      
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    5.0% (2)
    12

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

    FI

     

    FOOTNOTES

     

    (1)The shares of common stock reported in this row are held by Soleus Capital Master Fund, L.P. (“Master Fund”). Soleus Capital, LLC (“Soleus Capital”) is the sole general partner of Master Fund and thus holds voting and dispositive power over the shares held by Master Fund. Soleus Capital Group, LLC (“SCG”) is the sole managing member of Soleus Capital. Mr. Guy Levy is the sole managing member of SCG. Each of SCG, Soleus Capital and Mr. Guy Levy disclaims beneficial ownership of these securities held by Master Fund and this report shall not be deemed an admission that they are the beneficial owners of such securities for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or for any other purpose, except to the extent of their respective pecuniary interests therein.

     

    (2)This percentage is calculated based upon 13,957,324 shares of the common stock of the Issuer (“Common Stock”) outstanding as of November 3, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q for the period ended September 30, 2023 filed with the Securities and Exchange Commission on November 13, 2023 (the “Form 10-Q”).

     

    2

     

     

    CUSIP No. 92941V 308

     

    1 NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
    Soleus Capital, LLC
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

    (a) ☐

    (b) ☐

    3 SEC USE ONLY
     
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5 SOLE VOTING POWER
    0
    6 SHARED VOTING POWER
    703,868 (1)
    7 SOLE DISPOSITIVE POWER
    0
    8 SHARED DISPOSITIVE POWER
    703,868 (1) 

    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    703,868 (1)
    10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
    ☐      
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    5.0% (2)
    12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
    OO

     

    FOOTNOTES

     

    (1)The shares of common stock reported in this row are held by Master Fund. Soleus Capital is the sole general partner of Master Fund and thus holds voting and dispositive power over the shares held by Master Fund. SCG is the sole managing member of Soleus Capital. Mr. Guy Levy is the sole managing member of SCG. Each of SCG, Soleus Capital and Mr. Guy Levy disclaims beneficial ownership of these securities held by Master Fund and this report shall not be deemed an admission that they are the beneficial owners of such securities for purposes of Section 13(d) of the Exchange Act, or for any other purpose, except to the extent of their respective pecuniary interests therein.

     

    (2)This percentage is calculated based upon 13,957,324 shares of Common Stock outstanding as of November 3, 2023, as reported in the Form 10-Q.

     

    3

     

     

    CUSIP No. 92941V 308

     

    1 NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
    Soleus Capital Group, LLC
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

    (a) ☐

    (b) ☐

    3 SEC USE ONLY
     
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5 SOLE VOTING POWER
    0
    6 SHARED VOTING POWER
    703,868 (1)
    7 SOLE DISPOSITIVE POWER
    0
    8 SHARED DISPOSITIVE POWER
    703,868 (1) 

    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    703,868 (1)
    10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
    ☐      
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    5.0% (2)
    12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
    OO

     

    FOOTNOTES

     

    (1)The shares of common stock reported in this row are held by Master Fund. Soleus Capital is the sole general partner of Master Fund and thus holds voting and dispositive power over the shares held by Master Fund. SCG is the sole managing member of Soleus Capital. Mr. Guy Levy is the sole managing member of SCG. Each of SCG, Soleus Capital and Mr. Guy Levy disclaims beneficial ownership of these securities held by Master Fund and this report shall not be deemed an admission that they are the beneficial owners of such securities for purposes of Section 13(d) of the Exchange Act, or for any other purpose, except to the extent of their respective pecuniary interests therein.

     

    (2)This percentage is calculated based upon 13,957,324 shares of Common Stock outstanding as of November 3, 2023, as reported in the Form 10-Q.

     

    4

     

     

    CUSIP No. 92941V 308

     

    1 NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
    Guy Levy
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

    (a) ☐

    (b) ☐

    3 SEC USE ONLY
     
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5 SOLE VOTING POWER
    0
    6 SHARED VOTING POWER
    703,868 (1)
    7 SOLE DISPOSITIVE POWER
    0
    8 SHARED DISPOSITIVE POWER
    703,868 (1) 

    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    703,868 (1)
    10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
    ☐      
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    5.0% (2)
    12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
    IN

     

    FOOTNOTES

     

    (1)The shares of common stock reported in this row are held by Master Fund. Soleus Capital is the sole general partner of Master Fund and thus holds voting and dispositive power over the shares held by Master Fund. SCG is the sole managing member of Soleus Capital. Mr. Guy Levy is the sole managing member of SCG. Each of SCG, Soleus Capital and Mr. Guy Levy disclaims beneficial ownership of these securities held by Master Fund and this report shall not be deemed an admission that they are the beneficial owners of such securities for purposes of Section 13(d) of the Exchange Act, or for any other purpose, except to the extent of their respective pecuniary interests therein.

     

    (2)This percentage is calculated based upon 13,957,324 shares of Common Stock outstanding as of November 3, 2023, as reported in the Form 10-Q.

     

    5

     

     

    Item 1.

     

      (a) Name of Issuer
        VYNE Therapeutics Inc.

     

      (b) Address of Issuer’s Principal Executive Offices
       

    685 Route 202/206 N.
    Suite 301

    Bridgewater, N.J. 08807

     

    Item 2.

     

      (a) Name of Person(s) Filing
       

    Soleus Capital Master Fund, L.P.

    Soleus Capital, LLC

    Soleus Capital Group, LLC

    Guy Levy

     

      (b) Address of Principal Business Office or, if none, Residence
       

    Soleus Capital Master Fund, L.P.

    104 Field Point Road, 2nd Floor

    Greenwich, CT 06830

     

    Soleus Capital, LLC

    104 Field Point Road, 2nd Floor

    Greenwich, CT 06830

     

    Soleus Capital Group, LLC

    104 Field Point Road, 2nd Floor

    Greenwich, CT 06830

     

    Guy Levy

    c/o Soleus Capital Management, L.P

    104 Field Point Road, 2nd Floor

    Greenwich, CT 06830

     

      (c) Citizenship
       

    Soleus Capital Master Fund, L.P. – Cayman Islands

    Soleus Capital, LLC – Delaware

    Soleus Capital Group, LLC - Delaware

    Guy Levy – United States

     

      (d) Title of Class of Securities
        Common Stock, $0.0001 par value per share

     

      (e) CUSIP Number
        92941V 308

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

      (a) ☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
           
      (b) ☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

     

    6

     

     

      (c) ☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. ☐78c).
           
      (d) ☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).
           
      (e) ☐ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
           
      (f) ☐ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
           
      (g) ☐ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
           
      (h) ☐ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
           
      (i) ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
           
      (j) ☐ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J).
           
      (k) ☐ Group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:

     

    Item 4. Ownership.

     

    Reference is made to Items 5 – 11 on the preceding pages of this Schedule 13G.

     

    Master Fund held, as of the close of business on December 31, 2023, an aggregate of 703,868 shares of the common stock of the Issuer. As the general partner of Master Fund, Soleus Capital may be deemed to have shared power to vote or to direct the vote and to dispose or to direct the disposition of the shares held by Master Fund. As the sole managing member of Soleus Capital, SCG may be deemed to have shared power to vote or to direct the vote and to dispose or to direct the disposition of the shares held by Master Fund. As the sole managing member of SCG, Mr. Guy Levy may be deemed to have shared power to vote or direct the vote and to dispose or to direct the disposition of the Shares held by Master Fund.

     

    Neither the filing of this Schedule 13G nor any of its contents shall be deemed to constitute an admission that Mr. Levy, Soleus Capital or SCG is the beneficial owner of the shares of the common stock of the Issuer referred to herein for purposes of Section 13(d) of the Exchange Act, or for any other purpose, and such beneficial ownership is expressly disclaimed, except to the extent of their respective pecuniary interests therein.

     

    Item 5. Ownership of Five Percent or Less of a Class

     

    Not applicable.

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group

     

    Not applicable.

     

    Item 10. Certification
     

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose, or with the effect, of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    7

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

     

    Date: February 2, 2024 Soleus Capital Master Fund, L.P.
         
      By: Soleus Capital, LLC, its General Partner
         
      By: Soleus Capital Group, LLC, its Managing Manager
         
      By: /s/ Guy Levy
      Name: Guy Levy
      Title: Managing Member
         
    Date: February 2, 2024 Soleus Capital, LLC
         
      By: Soleus Capital Group, LLC, its Managing Manager
         
      By: /s/ Guy Levy
      Name: Guy Levy
      Title: Managing Member
         
    Date: February 2, 2024 Soleus Capital Group, LLC
         
      By: /s/ Guy Levy
      Name:  Guy Levy
      Title: Managing Member
         
    Date: February 2, 2024 /s/ Guy Levy
      Name: Guy Levy

     

    Footnotes:  
       
    Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)

     

    8

     

     

    EXHIBIT A

    JOINT FILING AGREEMENT

     

    Soleus Capital Master Fund, L.P., a Cayman Islands exempted limited partnership, Soleus Capital, LLC, a Delaware limited liability company, Soleus Capital Group, LLC, a Delaware limited liability company, and Guy Levy, an individual, hereby agree to file jointly the statement on Schedule 13G to which this Joint Filing Agreement is attached, and any amendments thereto which may be deemed necessary, pursuant to Regulation 13D-G under the Securities Exchange Act of 1934, as amended.

     

    It is understood and agreed that each of the parties hereto is responsible for the timely filing of such statement and any amendments thereto, and for the completeness and accuracy of the information concerning such party contained therein, but such party is not responsible for the completeness or accuracy of information concerning the other party unless such party knows or has reason to believe that such information is inaccurate.

     

    It is understood and agreed that a copy of this Agreement shall be attached as an exhibit to the statement on Schedule 13G, and any amendments hereto, filed on behalf of each of the parties hereto.

     

    Date: February 2, 2024 Soleus Capital Master Fund, L.P.
         
      By: Soleus Capital, LLC, its General Partner
         
      By: Soleus Capital Group, LLC, its Managing Manager
         
      By: /s/ Guy Levy
      Name: Guy Levy
      Title: Managing Member
         
    Date: February 2, 2024 Soleus Capital, LLC
         
      By: Soleus Capital Group, LLC, its Managing Manager
         
      By: /s/ Guy Levy
      Name: Guy Levy
      Title: Managing Member
         
    Date: February 2, 2024 Soleus Capital Group, LLC
         
      By: /s/ Guy Levy
      Name:  Guy Levy
      Title: Managing Member
         
    Date: February 2, 2024 /s/ Guy Levy
      Name: Guy Levy

     

     

    9

     

    Get the next $VYNE alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VYNE

    DatePrice TargetRatingAnalyst
    7/31/2025Buy → Neutral
    BTIG Research
    11/18/2024$8.00Buy
    BTIG Research
    12/6/2021$7.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $VYNE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    VYNE Therapeutics Reports 2025 Second Quarter Financial Results and Provides Business Update

    BRIDGEWATER, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (NASDAQ:VYNE) ("VYNE" or the "Company"), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need, today reported financial results as of and for the quarter ended June 30, 2025. The Company is actively evaluating opportunities to enhance the value of its pipeline programs. VYNE's oral BD2-selective BET inhibitor, VYN202, has recently demonstrated a promising efficacy signal in a Phase 1b clinical trial in moderate to severe plaque psoriasis, as well as disease-modifying potential across multiple tran

    8/14/25 8:00:00 AM ET
    $VYNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    VYNE Therapeutics Announces Topline Results from Phase 2b Trial with Repibresib Gel in Nonsegmental Vitiligo

    Trial Did Not Meet Primary Endpoint or Key Secondary Endpoint of F-VASI50 and F-VASI75 Nominally Statistically Significant Effects Observed in Key Secondary and Exploratory Endpoints of Change from Baseline in F-VASI and T-VASI at 3% Concentration Company Will Terminate Extension Phase of Trial and Seek External Partner for Continued Development of Repibresib BRIDGEWATER, N.J., July 30, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (NASDAQ:VYNE) ("VYNE" or the "Company"), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need, today announced topline results from its P

    7/30/25 8:00:00 AM ET
    $VYNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    VYNE Therapeutics Provides Program Update on Oral BET inhibitor VYN202

    BRIDGEWATER, N.J., July 02, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (NASDAQ:VYNE) ("VYNE" or the "Company"), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need, today provided a program update for VYN202 following the clinical hold issued by the U.S. Food and Drug Administration (FDA) in April for the Company's Phase 1b clinical trial in the treatment of moderate-to-severe plaque psoriasis. VYN202 is an oral small molecule BD2-selective bromodomain and extra-terminal domain (BET) inhibitor that is being developed for the treatment of immune-mediated diseases.   

    7/2/25 7:45:00 AM ET
    $VYNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VYNE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lepore Patrick G bought $43,800 worth of shares (15,000 units at $2.92), increasing direct ownership by 41% to 51,472 units (SEC Form 4)

    4 - VYNE Therapeutics Inc. (0001566044) (Issuer)

    1/16/25 6:06:19 PM ET
    $VYNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lepore Patrick G bought $50,778 worth of shares (13,000 units at $3.91), increasing direct ownership by 55% to 36,472 units (SEC Form 4)

    4 - VYNE Therapeutics Inc. (0001566044) (Issuer)

    11/17/23 5:03:12 PM ET
    $VYNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VYNE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    VYNE Therapeutics downgraded by BTIG Research

    BTIG Research downgraded VYNE Therapeutics from Buy to Neutral

    7/31/25 7:17:36 AM ET
    $VYNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BTIG Research initiated coverage on VYNE Therapeutics with a new price target

    BTIG Research initiated coverage of VYNE Therapeutics with a rating of Buy and set a new price target of $8.00

    11/18/24 7:58:59 AM ET
    $VYNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HC Wainwright & Co. resumed coverage on VYNE Therapeutics with a new price target

    HC Wainwright & Co. resumed coverage of VYNE Therapeutics with a rating of Buy and set a new price target of $7.00

    12/6/21 6:30:12 AM ET
    $VYNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VYNE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF SCIENTIFIC OFFICER Stuart Iain covered exercise/tax liability with 2,453 shares, decreasing direct ownership by 2% to 117,687 units (SEC Form 4)

    4 - VYNE Therapeutics Inc. (0001566044) (Issuer)

    10/2/25 5:05:09 PM ET
    $VYNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PRESIDENT AND CEO Domzalski David covered exercise/tax liability with 12,676 shares, decreasing direct ownership by 3% to 428,892 units (SEC Form 4)

    4 - VYNE Therapeutics Inc. (0001566044) (Issuer)

    10/2/25 5:05:05 PM ET
    $VYNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF FINANCIAL OFFICER Zeronda Tyler covered exercise/tax liability with 3,420 shares, decreasing direct ownership by 3% to 111,653 units (SEC Form 4)

    4 - VYNE Therapeutics Inc. (0001566044) (Issuer)

    10/2/25 5:05:10 PM ET
    $VYNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VYNE
    SEC Filings

    View All

    VYNE Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    8-K - VYNE Therapeutics Inc. (0001566044) (Filer)

    9/12/25 4:03:33 PM ET
    $VYNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by VYNE Therapeutics Inc.

    SCHEDULE 13G/A - VYNE Therapeutics Inc. (0001566044) (Subject)

    8/14/25 4:49:29 PM ET
    $VYNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    VYNE Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Financial Statements and Exhibits

    8-K - VYNE Therapeutics Inc. (0001566044) (Filer)

    8/14/25 8:05:47 AM ET
    $VYNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VYNE
    Leadership Updates

    Live Leadership Updates

    View All

    VYNE Therapeutics Announces Appointment of Subhashis Banerjee, M.D. as Senior Vice President of Clinical Development

    BRIDGEWATER, N.J., July 09, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (NASDAQ:VYNE) ("VYNE" or the "Company"), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced the appointment of Subhashis Banerjee, M.D., as Senior Vice President of Clinical Development, effective as of July 8, 2024. Dr. Banerjee is a trained immunologist and rheumatologist with over 25 years of drug development experience at large pharmaceutical companies, including with the development of therapies for psoriasis and arthritic conditions. "We are pleased to welcome Dr. Banerjee to the VYNE

    7/9/24 8:00:00 AM ET
    $VYNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    VYNE Therapeutics Appoints Christine Borowski, Ph.D., to its Board of Directors

    BRIDGEWATER, N.J., Jan. 03, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (NASDAQ:VYNE) ("VYNE" or the "Company"), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced the appointment of Christine Borowski, Ph.D., to its board of directors, effective as of January 1, 2024. "We are pleased to welcome Dr. Borowski to our Board of Directors during this important time in the Company's growth," said David Domzalski, President and CEO of VYNE. "With her expertise in immunology and extensive experience in the biopharmaceutical industry, Dr. Borowski will provide valuable p

    1/3/24 8:00:00 AM ET
    $VYNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VYNE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by VYNE Therapeutics Inc.

    SC 13G/A - VYNE Therapeutics Inc. (0001566044) (Subject)

    11/14/24 3:34:53 PM ET
    $VYNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by VYNE Therapeutics Inc. (Amendment)

    SC 13G/A - VYNE Therapeutics Inc. (0001566044) (Subject)

    2/14/24 4:57:08 PM ET
    $VYNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by VYNE Therapeutics Inc. (Amendment)

    SC 13G/A - VYNE Therapeutics Inc. (0001566044) (Subject)

    2/2/24 9:42:00 AM ET
    $VYNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VYNE
    Financials

    Live finance-specific insights

    View All

    VYNE Therapeutics Announces Reverse Stock Split

    BRIDGEWATER, N.J., Feb. 10, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (NASDAQ:VYNE) ("VYNE" or the "Company"), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that its Board of Directors has approved a reverse stock split of the Company's common stock at a ratio of 1-for-18. The reverse stock split was previously approved by stockholders at the Special Meeting of Stockholders on January 12, 2023. The reverse stock split will become effective after market close on Friday, February 10, 2023 and shares will begin trading on a split-adjusted basis when the market opens on Mo

    2/10/23 8:00:00 AM ET
    $VYNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    VYNE Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update

    Lead BET Inhibitor Candidate, VYN201, Demonstrates Potent Anti-Inflammatory Effect in Preclinical Studies VYN201 Expected to Enter Clinic in 2022 Phase 2a Results for FMX114 in Mild-to-Moderate Atopic Dermatitis Expected Early Q1 2022 Process for Sale of Topical Minocycline Franchise Continues to Advance Conference call and Live Webcast Today at 8:30 am Eastern Time BRIDGEWATER, N.J., Nov. 10, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (NASDAQ:VYNE) ("VYNE" or the "Company") today announced financial results for the third quarter ended September 30, 2021 and provided a business update. "The third quarter marks an important turning point for VYNE, as our company is now fully enga

    11/10/21 7:30:00 AM ET
    $VYNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    VYNE Therapeutics to Report Third Quarter 2021 Financial Results on November 10, 2021

    BRIDGEWATER, N.J., Oct. 28, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (NASDAQ:VYNE) ("VYNE" or the "Company") today announced that it will report its financial results for the third quarter ended September 30, 2021, on Wednesday, November 10, 2021, before the market opens. VYNE will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the financial results and provide a corporate update. Conference Call Details:Wednesday, November 10th @ 8:30am Eastern TimeToll Free:855-327-6837International:631-891-4304Conference ID:10017178Webcast:https://themediaframe.com/mediaframe/webcast.html?webcastid=44cKOFEX A replay of the call will be archived on the Company's website at

    10/28/21 8:00:00 AM ET
    $VYNE
    Biotechnology: Pharmaceutical Preparations
    Health Care